Recent Updates
Recently added Catalysts

measles, mumps, and rubella virus vaccine live

Phase 2

Measles | Monoclonal antibody | Other |Merck & Company, Inc.|Last Updated: Mar 15, 2017

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment1,210
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00092404Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)PHASE2 COMPLETED 1,210 — — Dec 1, 2001Jun 1, 2005Mar 15, 2017 - —
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Antibody response rates to measles, mumps, and rubella at 6 weeks postvaccination
6 weeks postvaccination
Secondary Endpoints
Geometric mean titers to measles, mumps, and rubella by ELISA at 6 weeks postvaccination
6 weeks postvaccination
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Interventions
NameTypeDescription
measles, mumps, and rubella virus vaccine liveBIOLOGICAL -
Comparator: Measles, Mumps, and Rubella Virus Vaccine LiveBIOLOGICAL -
Unlock Study Design Details
Eligibility Criteria
Age Range12 Months — 18 Months
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Healthy children 12 to 18 months of age Exclusion Criteria: * History or prior exposure to measles, mumps, or rubella * History of allergic reactions to any component of the vaccines as evaluated by the study doctor

Unlock Eligibility Criteria